Ultragenyx Pharmaceutical Inc
RARE33.760USD
+0.235+0.70%
Cierre 11/26, 16:00（ET）Cotizaciones retrasadas 15 min
3.26BCap. mercado
PérdidaP/E TTM
Más Datos de Ultragenyx Pharmaceutical Inc Compañía
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
Información de Ultragenyx Pharmaceutical Inc
Símbolo de cotizaciónRARE
Nombre de la empresaUltragenyx Pharmaceutical Inc
Fecha de salida a bolsaJan 31, 2014
Director ejecutivoDr. Emil D. Kakkis, M.D., Ph.D.
Número de empleados1294
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 31
Dirección60 Leveroni Ct
CiudadNOVATO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94949
Teléfono14154838800
Sitio Webhttps://www.ultragenyx.com/
Símbolo de cotizaciónRARE
Fecha de salida a bolsaJan 31, 2014
Director ejecutivoDr. Emil D. Kakkis, M.D., Ph.D.
Ejecutivos de Ultragenyx Pharmaceutical Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.69M
-1.17%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
107.20K
+41.78%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
41.99K
+83.47%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
27.34K
+26.57%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
27.34K
+26.57%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
20.59K
+38.64%
Dr. Amrit Ray, M.D.
Dr. Amrit Ray, M.D.
Independent Director
Independent Director
18.02K
+46.74%
Mr. Howard Horn
Mr. Howard Horn
Chief Financial Officer, Executive Vice President, Corporate Strategy
Chief Financial Officer, Executive Vice President, Corporate Strategy
7.75K
-50.61%
Mr. John R. Pinion, II
Mr. John R. Pinion, II
Chief Quality Officer, Executive Vice President - Translational Sciences
Chief Quality Officer, Executive Vice President - Translational Sciences
--
--
Mr. Eric Olson
Mr. Eric Olson
Chief Business Officer, Executive Vice President
Chief Business Officer, Executive Vice President
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.69M
-1.17%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
107.20K
+41.78%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
41.99K
+83.47%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
27.34K
+26.57%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
27.34K
+26.57%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
20.59K
+38.64%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Por negocioUSD
Nombre
Ganancia
Proporción
Crysvita royalty revenue
85.68M
51.46%
Crysvita
34.73M
20.86%
Dojolvi
23.21M
13.94%
Evkeeza
14.57M
8.75%
Mepsevii
8.31M
4.99%
Por regiónUSD
Nombre
Ganancia
Proporción
North America
102.93M
61.82%
Latin America
32.97M
19.80%
Europe
26.40M
15.86%
Japan
4.20M
2.52%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Crysvita royalty revenue
85.68M
51.46%
Crysvita
34.73M
20.86%
Dojolvi
23.21M
13.94%
Evkeeza
14.57M
8.75%
Mepsevii
8.31M
4.99%
Estadísticas de accionistas
Actualizado: mar., 18 de nov
Actualizado: mar., 18 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.48%
BlackRock Institutional Trust Company, N.A.
5.26%
Fidelity Management & Research Company LLC
4.07%
Sands Capital Management, LLC
3.91%
State Street Investment Management (US)
3.83%
Otro
72.46%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.48%
BlackRock Institutional Trust Company, N.A.
5.26%
Fidelity Management & Research Company LLC
4.07%
Sands Capital Management, LLC
3.91%
State Street Investment Management (US)
3.83%
Otro
72.46%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
51.75%
Investment Advisor/Hedge Fund
31.58%
Hedge Fund
15.20%
Individual Investor
3.48%
Research Firm
2.31%
Sovereign Wealth Fund
1.02%
Private Equity
1.02%
Pension Fund
0.52%
Bank and Trust
0.40%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
640
97.34M
100.90%
-3.53M
2025Q2
635
97.48M
101.32%
-2.63M
2025Q1
652
96.83M
102.45%
-3.19M
2024Q4
645
94.29M
102.32%
-4.54M
2024Q3
633
93.51M
101.49%
-6.93M
2024Q2
618
95.17M
101.90%
+3.05M
2024Q1
605
86.17M
101.67%
-4.74M
2023Q4
588
86.44M
105.27%
+5.64M
2023Q3
574
75.90M
106.07%
-3.60M
2023Q2
591
75.05M
105.07%
-3.13M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
10.19M
10.58%
+217.20K
+2.18%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.02M
5.21%
+106.89K
+2.18%
Jun 30, 2025
Fidelity Management & Research Company LLC
2.27M
2.36%
+1.89M
+495.36%
Jun 30, 2025
Sands Capital Management, LLC
3.94M
4.09%
-220.08K
-5.29%
Jun 30, 2025
State Street Investment Management (US)
2.57M
2.67%
-46.25K
-1.77%
Jun 30, 2025
RTW Investments L.P.
1.71M
1.77%
--
--
Jun 30, 2025
JP Morgan Asset Management
2.60M
2.7%
+2.56M
+5502.04%
Jun 30, 2025
Baker Bros. Advisors LP
2.77M
2.88%
+1.20M
+75.92%
Jun 30, 2025
Kakkis (Emil D)
2.69M
2.79%
-31.78K
-1.17%
Mar 07, 2025
Ver más
ETFs relacionados
Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
Motley Fool Small-Cap Growth ETF
3.15%
Global X Genomics & Biotechnology ETF
2.87%
Franklin Genomic Advancements ETF
1.35%
Virtus LifeSci Biotech Products ETF
1.27%
SPDR S&P Biotech ETF
1.21%
WisdomTree BioRevolution Fund
0.88%
Touchstone Sands Capital US Select Growth ETF
0.8%
Direxion Daily S&P Biotech Bull 3X Shares
0.63%
First Trust Multi-Manager Large Growth ETF
0.55%
Goldman Sachs Future Health Care Equity ETF
0.5%
Ver más
Motley Fool Small-Cap Growth ETF
Proporción3.15%
Global X Genomics & Biotechnology ETF
Proporción2.87%
Franklin Genomic Advancements ETF
Proporción1.35%
Virtus LifeSci Biotech Products ETF
Proporción1.27%
SPDR S&P Biotech ETF
Proporción1.21%
WisdomTree BioRevolution Fund
Proporción0.88%
Touchstone Sands Capital US Select Growth ETF
Proporción0.8%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.63%
First Trust Multi-Manager Large Growth ETF
Proporción0.55%
Goldman Sachs Future Health Care Equity ETF
Proporción0.5%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Ultragenyx Pharmaceutical Inc?
Los cinco principales accionistas de Ultragenyx Pharmaceutical Inc son:
The Vanguard Group, Inc. posee 10.19M acciones, lo que representa el 10.58% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 5.02M acciones, lo que representa el 5.21% del total de acciones.
Fidelity Management & Research Company LLC posee 2.27M acciones, lo que representa el 2.36% del total de acciones.
Sands Capital Management, LLC posee 3.94M acciones, lo que representa el 4.09% del total de acciones.
State Street Investment Management (US) posee 2.57M acciones, lo que representa el 2.67% del total de acciones.
The Vanguard Group, Inc. posee 10.19M acciones, lo que representa el 10.58% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 5.02M acciones, lo que representa el 5.21% del total de acciones.
Fidelity Management & Research Company LLC posee 2.27M acciones, lo que representa el 2.36% del total de acciones.
Sands Capital Management, LLC posee 3.94M acciones, lo que representa el 4.09% del total de acciones.
State Street Investment Management (US) posee 2.57M acciones, lo que representa el 2.67% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Ultragenyx Pharmaceutical Inc?
Los tres principales tipos de accionista de Ultragenyx Pharmaceutical Inc son:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Fidelity Management & Research Company LLC
¿Cuántas instituciones poseen acciones de Ultragenyx Pharmaceutical Inc (RARE)?
A fecha de 2025Q3, 640 instituciones poseen acciones de Ultragenyx Pharmaceutical Inc, con un valor de mercado combinado de aproximadamente 97.34M, lo que representa el 100.90% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en -0.43%.
¿Cuál es la mayor fuente de ganancias de Ultragenyx Pharmaceutical Inc?
El FY2025Q2, el segmento empresarial Crysvita royalty revenue generó la ganancia más alta para Ultragenyx Pharmaceutical Inc, ascendiendo a 85.68M y representando el 51.46% de la ganancia total.
